ADPT
Adaptive Biotechnologies Corporation
NASDAQ · USHealthcareBiotechnology
$21.86-4.62%
Price as of Jul 20, 2026
ADPT profitability
Adaptive Biotechnologies Corporation profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 75.3%
- EBITDA margin
- -7.5%
- EBIT margin
- -15.8%
- Net margin
- -16.8%
- Free cash flow margin
- -10.0%
Returns
- Return on equity
- -23.0%
- Return on assets
- -9.8%
- Return on invested capital
- -11.0%
- Asset turnover
- 0.58x
Cash efficiency
- Cash from operations
- -$27.0M
- Cash per share
- $1.36
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.